| Bioactivity | Velagliflozin is an orally available sodium-glucose cotransporter 2 (SGLT2) inhibitor, with anti-diabetic activity. | ||||||||||||
| Invitro | Velagliflozin 是一种钠-葡萄糖共转运蛋白 2 (SGLT2) 抑制剂，具有抗糖尿病活性[1]。 | ||||||||||||
| In Vivo | Velagliflozin (1 mg/kg, 口服, 单剂量) 增加胆固醇、白蛋白、β -羟基丁酸 (BHB)、非酯化脂肪酸 (NEFA) 和尿葡萄糖排泄，并降低猫的呼吸交换比率[1]。Velagliflozin (0.3 mg/kg; 口服; 每天 1 次, 共 18 天) 耐受性良好，可通过降低饮食非结构性碳水化合物 (NSC) 的高胰岛素反应来治疗小马的胰岛素失调和预防椎板炎[2]。 | ||||||||||||
| Name | Velagliflozin | ||||||||||||
| CAS | 946525-65-1 | ||||||||||||
| Formula | C23H25NO5 | ||||||||||||
| Molar Mass | 395.45 | ||||||||||||
| Appearance | Oil | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Hoenig M, et al. Effects of the sodium-glucose cotransporter 2 (SGLT2) inhibitor velagliflozin, a new drug with therapeutic potential to treat diabetes in cats. J Vet Pharmacol Ther. 2018 Apr;41(2):266-273. |